title: CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.
abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as gefitinib emerged as an accepted treatment in second- or third-line setting in NSCLC. However, clinical surrogate markers of EGFR-TKI activity in NSCLC patients remain to be identified and we studied the prognostic value of CYFRA 21-1 in this setting. Serum samples from 53 patients with NSCLC receiving gefitinib after failure of at least a platinum-containing regimen were prospectively collected from January 2002 to December 2003. Multivariate analysis demonstrated an independent negative impact on survival for a level of CYFRA 21-1 higher than 3.5 ng ml(-1) (HR=2.45, 95% CI 1.13-5.29; P=0.02). In conclusion, CYFRA 21-1 is a tool available to predict the survival of NSCLC patients receiving gefitinib as third-line therapy in an independent manner. In case of a CYFRA 21-1 level higher than 3.5 ng ml(-1), treatment with gefitinib needs further evaluation giving its relative poor effect on survival.
authors.affiliation: Department of Thoracic Oncology, Faculty of Medicine, Assistance Publique Hôpitaux de Marseille, Fédération des Maladies Respiratoires, Hôpital Sainte-Marguerite, 270, Bd de Sainte-Marguerite, 13274 Marseille Cedex 09, France. fabrice.barlesi@mail.ap-hm.fr
authors.forename: F
authors.initials: F
authors.lastname: Barlési
authors.forename: C
authors.initials: C
authors.lastname: Tchouhadjian
authors.forename: C
authors.initials: C
authors.lastname: Doddoli
authors.forename: J-P
authors.initials: JP
authors.lastname: Torre
authors.forename: P
authors.initials: P
authors.lastname: Astoul
authors.forename: J-P
authors.initials: JP
authors.lastname: Kleisbauer
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D053539:Keratin-19; D007633:Keratins; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047908:Intracellular Signaling Peptides and Proteins; D053539:Keratin-19; D011799:Quinazolines; C102012:antigen CYFRA21.1; C015482:protein kinase modulator; D007633:Keratins; D000077156:Gefitinib